<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The use of <z:chebi fb="0" ids="35666">thiopurines</z:chebi> as immunosuppression for the treatment of refractory or <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> is established for both <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Nevertheless, many questions remain concerning the optimal treatment regimens of <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, <z:chebi fb="1" ids="50667">6-mercaptopurine</z:chebi> and thioguanine </plain></SENT>
<SENT sid="2" pm="."><plain>We will briefly summarize dose recommendations, indications for <z:chebi fb="0" ids="35666">thiopurine</z:chebi> therapy and side effects which are relevant in clinical practice </plain></SENT>
<SENT sid="3" pm="."><plain>We discuss some currently debated topics, including the combination of <z:chebi fb="2" ids="2948">azathioprine</z:chebi> and <z:chebi fb="0" ids="40279">allopurinol</z:chebi>, switching of <z:chebi fb="0" ids="35666">thiopurine</z:chebi> therapy in case of side effects, the use of <z:chebi fb="2" ids="2948">azathioprine</z:chebi> in pregnancy, the <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> risk using <z:chebi fb="0" ids="35666">thiopurines</z:chebi> and the evidence when to stop <z:chebi fb="0" ids="35666">thiopurines</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Excellent reviews have been published on the <z:chebi fb="0" ids="35666">thiopurine</z:chebi> metabolic pathway which will not be discussed here in detail </plain></SENT>
</text></document>